| 1. |
US FDA's response to flu vaccine shortage |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1465,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
Essential drugs concept the answer to rising costs in the West? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1465,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
Importance of long-acting atypical antipsychotic agents |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1465,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
All eyes on latanoprost for open-angle glaucoma |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1465,
2004,
Page 5-6
&NA;,
Preview
|
|
摘要:
Glaucoma is one of the leading causes of preventable blindness worldwide. It has been estimated that around 3 million individuals in the US have open-angle glaucoma, half of whom are unaware they have the disease. Blindness due to glaucoma currently affects approximately 120 000 US individuals, and costs the US government more than $US1.5 billion annually in social security benefits, lost income and tax revenues and healthcare expenditures. The aim of glaucoma treatment is to lower and then maintain low intraocular pressure (IOP), to halt the progression of the disease. Latanoprost ophthalmic solution [Xalatan] is a prostaglandin F2αanalogue which acts locally in the eye to increase drainage of aqueous humor and reduce IOP. It is indicated for use among patients with open-angle glaucoma or ocular hypertension. The economic effects of latanoprost treatment in patients with open-angle glaucoma were evaluated by a number of researchers presenting their work at a poster session at the 7th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research [ISPOR; Hamburg, Germany, October 2004].
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
Although analgesic selection appears to be"quite rational"among dental outpatients in Nepal, there are some areas of concern, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1465,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
Aprinocarsen/cisplatin/gemcitabine may have activity in NSCLC |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1465,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
Budesonide/formoterol for superior asthma control |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1465,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
Further evidence for BP reduction with statins |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1465,
2004,
Page 9-10
S Sullivan,
Preview
|
|
摘要:
Statin therapy produces modest and reversible reductions in BP, according to studies presented at the Annual Scientific Sessions of the American Heart Association (AHA) [New Orleans, US; November 2004]. Reductions in diastolic and systolic BP were observed with pravastatin and simvastatin in the UCSD Statin Study. An analysis of data from the ASCOT-LLA study found that atorvastatin treatment was associated with a small but significant reduction in BP, compared with placebo.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Short-course ciprofloxacin for UTIs equivalent to longer treatments |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1465,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
Sirolimus vs azathioprine in heart transplantation |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1465,
2004,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
